Novartis

News

UK biotech Dunad inks $1.3bn Novartis deal for its protein d...

In only its second year of operations, Cambridge, UK startup Dunad Therapeutics has already attracted a big pharma partner for its protein degradation platform.

News

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

Novartis has claimed FDA approval for one of its 'wild card' drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML).

News

Novartis looking into future of its Sandoz' generics busines...

Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines.

News

Strike two for Novartis' lung cancer antibody canakinumab

Expectations for Novartis' canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objecti

News

FDA clears Roche's Susvimo implant for eye disease wet AMD

Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular inj

News

Female doctor with the stethoscope holding heart

Novartis-backed project mobilises patient power against hear...

Novartis has joined forces with a group representing cardiovascular disease patients organisations to push for changes in how health systems handle the world's number one killer.

UK biotech Dunad inks $1.3bn Novartis deal for its protein d...

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

Novartis looking into future of its Sandoz' generics busines...

Strike two for Novartis' lung cancer antibody canakinumab

FDA clears Roche's Susvimo implant for eye disease wet AMD

Novartis-backed project mobilises patient power against hear...

Roche, Viking, and Syntis showcase obesity drug candidates

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks